sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
caus
atyp
pneumonia
affect
asia
north
america
europ
viral
spike
glycoprotein
respons
mediat
receptor
bind
membran
fusion
recent
studi
propos
carboxyl
termin
portion
subunit
protein
class
viral
fusion
protein
wimley
white
interfaci
hydrophob
scale
use
identifi
region
within
cov
subunit
may
preferenti
associ
lipid
membran
premis
peptid
analog
region
may
function
inhibitor
viral
infect
five
region
high
interfaci
hydrophob
span
length
subunit
sarscov
murin
hepat
viru
mhv
identifi
peptid
analog
region
nterminu
pretransmembran
domain
subunit
inhibit
sarscov
plaqu
format
concentr
interestingli
peptid
analog
sarscov
mhv
loop
region
inhibit
viral
plaqu
format
similar
concentr
observ
effect
dosedepend
valu
result
peptidemedi
cell
cytotox
antivir
activ
cov
peptid
test
provid
attract
basi
develop
new
fusion
peptid
inhibitor
correspond
region
outsid
fusion
protein
heptad
repeat
region
sever
acut
respiratori
syndrom
sar
atyp
pneumonia
character
influenzalik
symptom
includ
fever
cough
dyspnea
headach
epidem
produc
overal
mortal
approxim
result
death
countri
worldwid
holm
peiri
et
al
etiolog
agent
sar
sarscov
quickli
identifi
belong
famili
coronavirida
group
larg
envelop
rna
virus
exhibit
broad
host
rang
capabl
caus
respiratori
hepat
enter
diseas
lai
holm
siddel
initi
phylogenet
analys
sequenc
comparison
reveal
signific
differ
sarscov
cov
distinguish
uniqu
group
group
unrel
previous
character
cov
group
drosten
et
al
ksiazek
et
al
peiri
et
al
recent
analys
howev
report
sarscov
close
resembl
group
cov
therefor
classifi
subgroup
within
group
gorbalenya
et
al
magiorkini
et
al
song
et
al
phylogen
analys
studi
investig
ancestr
origin
sarscov
yield
consensu
regard
proper
group
nonetheless
anim
reservoir
sarscov
appear
exist
reemerg
uniqu
cov
highli
probabl
therefor
threat
new
sar
outbreak
remain
constant
public
health
concern
like
envelop
virus
cov
enter
target
cell
induc
fusion
viral
cellular
membran
process
mediat
viral
spike
glycoprotein
gallagh
buchmeier
subunit
protein
mediat
receptor
bind
cavanagh
davi
taguchi
subunit
respons
drive
viral
target
cell
membran
fusion
taguchi
shimazaki
case
sarscov
subunit
bind
mammalian
receptor
angiotensinconvert
enzym
huang
et
al
li
et
al
li
et
al
wang
et
al
wong
et
al
andor
jeffer
et
al
initi
entri
process
via
cathepsin
ldepend
pathway
huang
et
al
analysi
murin
hepat
viru
mhv
sarscov
protein
xu
et
al
b
c
reveal
common
structur
featur
share
class
viral
fusion
protein
gallah
gallah
et
al
includ
hydrophob
fusion
peptid
sainz
et
al
pair
extend
helic
nhelix
chelix
tripet
et
al
loop
domain
separ
two
helic
cluster
aromat
amino
acid
sainz
et
al
proxim
hydrophob
transmembran
anchor
domain
class
viral
fusion
protein
mediat
viral
target
cell
membran
fusion
seri
conform
chang
involv
insert
fusion
peptid
target
cell
membran
trimer
extens
heptad
repeat
hr
helic
toward
target
membran
subsequ
format
sixhelix
coiledcoil
bundl
gallah
structur
trimer
helic
form
central
coiledcoil
surround
three
helic
antiparallel
mode
xu
et
al
loop
region
believ
act
hing
facilit
sixhelix
coiledcoil
bundl
format
mediat
membran
juxtaposit
current
model
viral
cell
membran
fusion
hypothet
aspect
import
sever
structuralfunct
motif
class
viral
fusion
protein
drug
develop
target
establish
exampl
analog
orthomyxoviru
paramyxoviru
richardson
et
al
fusion
peptid
domain
gallah
et
al
owen
et
al
silburn
et
al
block
viral
infect
presum
form
inact
heteroaggreg
likewis
peptid
analog
hr
region
gallah
et
al
qureshi
et
al
wild
et
al
wild
et
al
paramyxoviru
lambert
et
al
young
et
al
ebola
viru
ebov
watanab
et
al
class
viral
fusion
protein
block
virion
infect
prevent
transit
fusion
protein
sixhelix
bundl
state
peptid
drug
fuzeon
tm
enfuvirtid
overlap
aromat
domain
first
new
class
fusion
inhibitor
antivir
gain
fda
approv
peptid
shown
potent
inhibit
virion
cell
fusion
low
concentr
inhibit
nm
vitro
wild
et
al
likewis
clinic
trial
mgday
fuzeon
tm
caus
reduct
plasma
load
infect
individu
kilbi
et
al
lalezari
et
al
b
result
substanti
valid
efficaci
new
class
antivir
greatli
motiv
search
peptid
fusion
inhibitor
design
target
virus
sarscov
gallah
garri
kliger
levanon
date
studi
examin
peptid
fusion
inhibitor
cov
examin
efficaci
peptid
analog
hr
region
viral
fusion
protein
bosch
et
al
first
demonstr
peptid
analog
helix
mhv
subunit
could
block
viral
entri
concentr
sever
group
later
show
andor
peptid
could
likewis
inhibit
sarscov
entri
replic
liu
et
al
yuan
et
al
zhu
et
al
antivir
capac
peptid
attribut
inher
interact
tripet
et
al
xu
et
al
c
peptid
analog
either
one
two
hr
region
believ
directli
inhibit
endogen
interact
prevent
format
sixhelix
bundl
although
hr
analog
appear
effect
inhibitor
sarscov
entri
vitro
develop
peptid
fusion
inhibitor
base
nonhr
region
viral
fusion
protein
yet
explor
employ
novel
approach
identifi
new
peptid
inhibitor
sarscov
use
wimley
white
ww
interfaci
hydrophob
scale
ih
wimley
white
identifi
five
region
within
sarscov
mhv
subunit
high
propens
interact
lipid
interfac
membran
region
span
entir
subunit
may
play
import
role
viral
fusion
protein
target
cell
membran
interact
may
therefor
repres
possibl
target
therapeut
interfer
result
demonstr
peptid
analog
region
high
interfaci
hydrophob
effect
inhibitor
sarscov
infect
particular
peptid
analog
loop
region
andor
ntermin
region
subunit
potent
inhibit
cov
plaqu
format
concentr
less
gml
find
provid
altern
approach
develop
viral
peptid
inhibitor
allow
identif
possibl
therapeut
peptid
outsid
hr
region
class
viral
fusion
protein
mhv
sarscov
synthet
peptid
synthes
solidphas
methodolog
use
semiautom
peptid
synthes
convent
chemistri
genem
synthesi
inc
san
francisco
ca
peptid
purifi
reversedphas
high
perform
liquid
chromatographi
puriti
confirm
amino
acid
analysi
electrospray
mass
spectrometri
peptid
stock
solut
prepar
dimethyl
sulfoxid
dmso
spectroscopi
grade
h
vv
concentr
determin
spectroscop
smartspec
tm
biorad
hercul
ca
vero
cell
american
type
cultur
collect
manassa
va
maintain
minimum
essenti
medium
mem
dulbecco
modifi
eagl
medium
dmem
respect
supplement
fetal
bovin
serum
fb
penicillin
g
uml
streptomycin
mgml
mm
lglutamin
c
co
sarscov
strain
urbani
propag
vero
cell
mhv
strain
atcc
propag
cell
plaqu
reduct
assay
vero
cell
cell
seed
densiti
cell
well
plate
h
h
prior
infect
approxim
plaqu
form
unit
pfu
either
sarscov
strain
urbani
mhv
preincub
peptid
without
peptid
diluent
control
serumfre
mem
sarscov
serumfre
dmem
mhv
h
c
vero
cell
infect
peptideor
vehicletr
sarscov
inoculum
peptideor
vehicletr
mhv
inoculum
respect
h
adsorpt
inoculum
remov
cell
wash
twice
phosphat
buffer
salin
pb
overlaid
fbsmem
fbsdmem
contain
nobl
agar
sigma
rockland
cell
fix
day
pi
formalin
h
room
temperatur
stain
crystal
violet
visual
plaqu
vero
cell
stain
neutral
red
day
pi
plaqu
number
determin
h
later
cell
viabil
determin
use
tac
tm
mtt
assay
r
system
inc
minneapoli
ca
accord
manufactur
instruct
briefli
vero
cell
cell
seed
densiti
cell
well
plate
h
prior
treatment
cell
subsequ
treat
medium
diluentcontrol
gml
peptid
h
prior
addit
tetrazolium
compound
mtt
follow
incub
subsequ
addit
deterg
absorb
read
nm
spectrophotomet
cd
spectra
record
jasco
spectropolarimet
jasco
inc
easton
md
use
mm
path
length
nm
bandwidth
respons
time
scan
speed
nmmin
cd
run
perform
room
temperatur
peptid
dissolv
mm
phosphat
po
buffer
ph
three
success
scan
nm
collect
cd
data
express
mean
residu
ellipt
deriv
formula
deg
cm
dmol
method
deriv
gener
model
surfac
glycoprotein
describ
previous
gallah
et
al
domain
high
interfaci
hydrophob
identifi
membran
protein
explor
mpex
stephen
white
laboratori
http
blancobiomoluciedumpex
mpex
detect
membran
span
sequenc
base
experiment
determin
hydrophob
scale
white
wimley
wimley
white
data
present
mean
standard
error
mean
sem
data
peptidetr
group
compar
vehicletr
group
signific
differ
determin
oneway
analysi
varianc
anova
follow
tukey
post
hoc
ttest
graphpad
san
diego
ca
previou
studi
potenti
peptid
inhibitor
cov
examin
efficaci
peptid
correspond
helic
region
hr
region
subunit
liu
et
al
yuan
et
al
zhu
et
al
develop
addit
peptid
fusion
inhibitor
base
domain
viral
fusion
protein
promin
helic
yet
explor
use
comput
approach
identifi
region
sarscov
fusion
protein
potenti
interact
bilay
membran
wimley
white
wwih
experimentallydetermin
algorithm
use
estim
propens
amino
acid
sequenc
interact
lipid
membran
interfac
wimley
white
five
region
high
interfaci
hydrophob
within
sarscov
region
identifi
use
membran
protein
explor
mpex
http
blancobiomoluciedumpex
comput
program
base
wwih
fig
wwi
wwii
peptid
correspond
aminoterminu
region
predict
contain
fusion
peptid
sainz
et
al
wwiii
wwiv
peptid
correspond
loop
domain
wwv
peptid
correspond
aromat
domain
latter
highli
conserv
region
among
coronavirida
famili
also
present
class
viral
fusion
protein
otherwis
dispar
rna
virus
ebov
sainz
et
al
transmembran
domain
region
also
score
high
wwih
fig
investig
anchor
within
viral
membran
expos
viral
entri
although
sarscov
protein
share
amino
acid
sequenc
similar
protein
mhv
five
analog
locat
sequenc
high
interfaci
hydrophob
identifi
subunit
mhv
strain
fig
strain
bhk
data
shown
interfaci
hydrophob
plot
mean
valu
window
residu
gener
use
wwih
individu
residu
wimley
white
region
correspond
area
high
interfaci
hydrophob
identifi
sarscov
mhv
cov
subunit
highlight
black
bar
label
wwiwwv
hydrophob
score
kcalmol
indic
schemat
diagram
cov
protein
depict
hydrophob
plot
illustr
respect
domain
hr
heptad
repeat
aromat
domain
tm
transmembran
domain
arrow
indic
locat
minimum
furin
cleavag
site
molloy
et
al
present
protein
sarscov
rntr
residu
bergeron
et
al
mhv
rrahrsv
residu
luytj
et
al
synthet
peptid
correspond
sequenc
signific
wwih
score
synthes
tabl
exam
ine
abil
inhibit
either
sarscov
plaqu
format
vero
cell
peptid
concentr
fig
sar
wwi
sarswwii
inhibit
viral
plaqu
format
respect
sar
wwva
howev
show
inhibitori
effect
concentr
peptid
particular
interest
model
peptid
inhibitor
fuzeon
tm
kilbi
et
al
correspond
cterminu
chelix
aromat
domain
previou
work
laboratori
shown
aromat
domain
sarscov
mhv
subunit
partit
membran
lipid
vesicl
capabl
compromis
membran
integr
sainz
et
al
hypothes
inabl
sar
wwva
inhibit
sarscov
entri
may
due
propens
partit
lipid
interfac
sainz
et
al
wwv
deriv
five
amino
acid
truncat
aromat
domain
sar
wwvb
tabl
capabl
inhibit
sarscov
plaqu
format
fig
peptid
correspond
loop
region
sarscov
fusion
protein
effect
inhibit
sarscov
plaqu
format
sar
wwiii
sar
wwiv
inhibit
viral
plaqu
format
respect
fig
shown
fig
repres
photograph
sarscov
plaqu
format
presenc
two
peptid
consist
experiment
result
present
fig
sarscov
plaqu
effici
significantli
inhibit
presenc
sar
wwiii
sar
wwiv
compar
vehicletr
control
fig
versu
b
confirm
observ
antivir
activ
peptid
test
consequ
cellular
cytotox
cell
subsequ
infect
h
overlaid
medium
contain
agaros
day
pi
plaqu
number
determin
percent
inhibit
plaqu
format
calcul
plaqu
peptidetreatedno
plaqu
vehicletr
signific
reduct
plaqu
number
rel
vehicletr
cultur
denot
singl
asterisk
p
oneway
anova
tukey
post
hoc
ttest
vero
cell
infect
pfu
sarscov
strain
urbani
follow
h
incub
b
vehicl
c
sar
wwiii
sar
wwiv
cell
stain
neutral
red
day
pi
cultur
photograph
h
later
arrow
indic
repres
sarscov
plaqu
e
sarscov
peptid
affect
cell
viabil
vero
cell
treat
h
sarscov
peptid
cell
viabil
measur
use
tac
tm
mtt
assay
absorb
od
plot
untreat
u
diluenttr
peptidetr
cultur
mtt
assay
perform
describ
section
cell
treat
tetrazolium
compound
mtt
reduc
metabol
activ
viabl
cell
purpl
formazan
dye
crystal
absorb
od
solubil
crystal
peptidetr
diluenttr
group
compar
untreat
control
vero
cell
treat
sarscov
peptid
show
differ
absorb
compar
untreat
cell
likewis
diminish
cell
viabil
observ
cell
treat
diluent
control
fig
data
indic
antivir
capac
sarscov
peptid
result
cell
cytotox
could
directli
affect
cov
plaqu
format
potent
antivir
effect
observ
sarscov
loop
peptid
prompt
us
test
whether
peptid
analog
region
locat
within
loop
mhv
fusion
protein
similar
antivir
efficaci
illustr
fig
mhv
fusion
protein
also
contain
five
region
high
interfaci
hydrophob
determin
wwih
similar
sarscov
fusion
protein
two
region
mhv
wwiii
mhv
wwiv
locat
within
mhv
loop
region
synthet
peptid
correspond
two
region
tabl
synthes
examin
abil
inhibit
mhv
strain
plaqu
format
cell
peptid
concentr
mhv
wwiii
mhv
wwiv
inhibit
viral
plaqu
format
respect
data
shown
unlik
synthet
sarscov
loop
peptid
test
sar
wwiii
sar
wwiv
one
mhv
loop
peptid
mhv
wwiv
significantli
inhibit
mhv
plaqu
format
cell
potent
antivir
activ
mhv
wwiv
illustr
fig
compar
vehicletr
control
mhv
plaqu
effici
significantli
inhibit
presenc
mhv
wwiv
fig
versu
b
moreov
similar
mtt
assay
result
observ
sarscov
peptid
mhv
wwiv
peptid
cytotox
concentr
cell
data
shown
base
result
present
chose
examin
inhibitori
potenti
sar
wwiii
sar
wwiv
mhv
wwiv
peptid
achiev
level
inhibit
greater
concentr
doserespons
curv
gener
peptid
percent
inhibit
viral
plaqu
format
plot
function
peptid
concentr
fig
inhibit
effici
peptid
maintain
low
concentr
inhibitori
concentr
ic
sar
wwiii
sar
wwiv
approxim
fig
b
sarscov
peptid
statist
ineffect
concentr
less
data
shown
similarli
ic
valu
mhv
wwiv
fig
addit
sarscov
loop
peptid
ineffect
inhibitor
mhv
infect
suggest
degre
sequencespecif
inhibit
data
shown
hr
peptid
inhibitor
sarscov
mhv
structur
inhibit
viral
entri
coil
coil
interact
bosch
et
al
liu
et
al
zhu
et
al
assess
propens
loop
peptid
studi
herein
adopt
defin
secondari
structur
peptid
examin
cd
spectroscopi
fig
distinct
minima
nm
minima
nm
spectra
observ
peptid
mm
po
buffer
ph
rather
spectra
peptid
buffer
show
singl
minima
near
nm
indic
random
coil
sar
wwi
sar
wwii
independ
identifi
put
fusion
peptid
sarscov
protein
use
biophys
approach
sainz
et
al
peptid
analog
class
fusion
peptid
often
antivir
activ
gallah
et
al
owen
et
al
silburn
et
al
observ
wwi
andor
wwii
sequenc
inhibit
infect
fig
provid
evid
role
initi
cov
virion
cell
fusion
howev
rule
fusion
peptid
sarscov
may
posit
differ
class
fusion
protein
eg
loop
domain
wwiii
wwiv
membran
interact
conform
chang
cov
undergo
may
follow
exact
mechan
sar
wwiii
sar
wwiv
mhv
wwiv
correspond
sequenc
sarscov
mhv
loop
domain
exhibit
antivir
activ
greater
peptid
studi
inhibit
viral
plaqu
format
valu
fig
compound
inhibit
viru
replic
low
rang
consid
promis
lead
compound
sia
et
al
inhibit
plaqu
format
like
stringent
test
viral
inhibitor
although
differ
method
use
quantifi
antivir
effect
concentr
similar
lower
peptid
inhibitor
correspond
hr
region
cov
previous
identifi
exampl
helic
inhibitor
describ
bosch
et
al
liu
et
al
exhibit
rang
studi
requir
defin
mechan
nonhel
peptid
sar
wwiii
sar
wwiv
mhv
wwiv
inhibit
cov
infect
hypothes
peptid
may
steric
hinder
loop
prevent
either
initi
extens
fusion
protein
transit
sixhelix
bundl
state
interact
subunit
cellular
membran
recent
studi
york
nunberg
indic
tryptophan
residu
loop
domain
tm
critic
interact
surfac
glycoprotein
su
therefor
inhibitori
loop
peptid
may
disrupt
analog
region
interact
also
current
conflict
evid
whether
sarscov
undergo
cleavag
subunit
bergeron
et
al
wu
et
al
mhv
entri
sensit
lysosomotrop
agent
current
evid
indic
mhv
enter
cell
direct
fusion
plasma
membran
de
haan
et
al
simmon
et
al
report
inhibitor
endosom
acidif
impair
entri
retrovir
pseudotyp
particl
bear
sarscov
therefor
peptid
inhibitor
identifi
may
block
smediat
membran
fusion
differ
step
sarscov
mhv
plasma
membran
within
endosom
compart
altern
inhibitori
peptid
may
interact
directli
cov
virion
studi
requir
elucid
mechan
sarscov
mhv
peptid
inhibit
infect
cov
inhibitori
loop
peptid
identifi
propens
adopt
either
secondari
structur
determin
circular
dichroism
analysi
fig
increas
secondari
structur
exampl
addit
alanin
residu
promot
helix
format
jayasingh
et
al
may
increas
antivir
activ
studi
current
underway
evalu
hypothesi
investig
modif
cov
inhibitori
peptid
may
enhanc
therapeut
potenti
strategi
treatment
sar
patient
includ
broadspectrum
antibiot
glucocorticoid
ribavirin
howev
efficaci
treatment
still
unclear
therefor
order
develop
better
treatment
strategi
futur
outbreak
imper
develop
new
therapeut
studi
provid
data
support
investig
peptid
inhibitor
potenti
therapeut
sarscov
infect
immun
respons
sarscov
appear
capabl
individu
clear
infect
thu
therapeut
inhibit
viral
infect
reduc
sarscov
load
may
extend
window
time
effect
immun
respons
could
aris
